[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623491":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":42,"locations":47,"responsibleParty":78,"collaborators":80,"id":85,"slug":29,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":29,"eligibilityCriteria":89,"healthyVolunteers":86,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":29,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":106,"whyStopped":29,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-020","ACTIVE_COMPARATOR","Topical DA-020 Solution",[13],"Drug: DA-020",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Topical Placebo Solution",[19],"Drug: Placebo",{"label":21,"type":10,"description":21,"interventionNames":22},"DA-020 and Hyperforin (1.5%)",[23],"Drug: DA-020 and Hyperforin",[25,30,33],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","7mL application of DA-020 (Topical Oxymetazoline)",[9],null,{"type":26,"name":15,"description":31,"armGroupLabels":32,"otherNames":29},"Topical placebo solution",[15],{"type":26,"name":34,"description":35,"armGroupLabels":36,"otherNames":29},"DA-020 and Hyperforin","7mL application of DA-020 (Topical Oxymetazoline) and Hyperforin (1.5%)",[21],[38],{"name":39,"affiliation":40,"role":41},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[43],{"name":39,"role":44,"phone":45,"phoneExt":29,"email":46},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",[48,66],{"facility":49,"status":29,"city":50,"state":29,"zip":29,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Hospital Samel","Manaus","Brazil","BR",{"type":54,"coordinates":55},"Point",[56,57],-60.025,-3.10194,{"lat":57,"lon":56},[60,64],{"name":61,"role":44,"phone":62,"phoneExt":29,"email":63},"Daniel Fonseca, MD","+55 92 2129-2200","clinicalstudies@appliedbilogy.com",{"name":61,"role":65,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"facility":67,"status":29,"city":68,"state":29,"zip":29,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"University of Rome (\"G. Marconi\")","Rome","Italy","IT",{"type":54,"coordinates":72},[73,74],12.51133,41.89193,{"lat":74,"lon":73},[77],{"name":39,"role":44,"phone":45,"phoneExt":29,"email":46},{"type":79,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[81,83],{"name":82,"class":6},"Daniel Alain, Inc.",{"name":84,"class":6},"Follea International Limited","100623491",false,"NCT07397325","Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia","Inclusion Criteria:\n\n* Diagnosed with stage I or stage II breast cancer\n* Scheduled but not begun, at least 4 cycles of taxane and\u002For anthracycline-based chemotherapy.\n* Ages 18-65\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Resting blood pressure outside the range of 105-140\u002F 55-99\n* Uncontrolled or severe hypertension\n* Female pattern hair loss or hair loss disorder\n* Folliculitis\n* Scalp psoriasis\n* Seborrheic dermatitis\n* Inflammatory scalp conditions such as lichen planopillaris\n* Subjects wearing wigs prior to chemotherapy\n* Use of MAO inhibitors\n* Unable to provide consent or make allotted clinical visits","FEMALE","18 Years","65 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE1","PHASE2","Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia",[102,103],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[102,105],"Chemotherapy Alopecia","NOT_YET_RECRUITING","2026-04-08",{"date":109,"type":110},"2026-04-13","ACTUAL",{"date":112,"type":95},"2026-04-16",{"date":114,"type":95},"2026-12-07",{"name":5,"class":6},2]